Living Cell Technologies Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LVCLY research report →
Companywww.lctglobal.com
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
- CEO
- David Richard Hainsworth
- IPO
- 2008
- Employees
- 48
- HQ
- Sydney, NSW, AU
Price Chart
Valuation
- Market Cap
- $11.39M
- P/E
- -11.55
- P/S
- 195.96
- P/B
- 8.03
- EV/EBITDA
- -13.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1659.45%
- Net Margin
- -1673.77%
- ROE
- -61.85%
- ROIC
- -68.93%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-2,095,562 · 0.57%
- EPS
- $-0.01 · 18.75%
- Op Income
- $-2,200,720
- FCF YoY
- 23.31%
Performance & Tape
- 52W High
- $0.08
- 52W Low
- $0.02
- 50D MA
- $0.04
- 200D MA
- $0.05
- Beta
- 0.76
- Avg Volume
- 919
Get TickerSpark's AI analysis on LVCLY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LVCLY Coverage
We haven't published any research on LVCLY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LVCLY Report →